Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]

TY - JOUR

T1 - Glucose management for exercise using continuous glucose monitoring

T2 - should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]

AU - Moser, Othmar

AU - Riddell, Michael C

AU - Eckstein, Max L

AU - Adolfsson, Peter

AU - Rabasa-Lhoret, Rémi

AU - van den Boom, Louisa

AU - Gillard, Pieter

AU - Nørgaard, Kirsten

AU - Oliver, Nick S

AU - Zaharieva, Dessi P

AU - Battelino, Tadej

AU - de Beaufort, Carine

AU - Bergenstal, Richard M

AU - Buckingham, Bruce

AU - Cengiz, Eda

AU - Deeb, Asma

AU - Heise, Tim

AU - Heller, Simon

AU - Kowalski, Aaron J

AU - Leelarathna, Lalantha

AU - Mathieu, Chantal

AU - Stettler, Christoph

AU - Tauschmann, Martin

AU - Thabit, Hood

AU - Wilmot, Emma G

AU - Sourij, Harald

AU - Smart, Carmel E

AU - Jacobs, Peter G

AU - Bracken, Richard M

AU - Mader, Julia K

N1 - Funding Information: OM has received lecture fees from Medtronic, travel grants from Novo Nordisk A/S, Novo Nordisk AT, Novo Nordisk UK and Medtronic AT, research grants from S\u00EAr Cymru II COFUND fellowship/European Union, Sanofi-Aventis, Novo Nordisk A/S, Novo Nordisk AT, Dexcom Inc., as well as material funding from Abbott Diabetes Care. MCR has received speaker\u2019s honorarium from Medtronic and Insulet and has served on advisory boards for Dexcom, Sanofi and Eli Lilly. MLE has received a KESS2/European Social Fund scholarship and travel grants from Novo Nordisk A/S and Sanofi-Aventis. PA has received research support or advisory board fees from Eli Lilly, Novo Nordisk and Roche, funding from Research and Development, Region Halland, and is an employee of Region Halland. RRL reports having received a consumable gift (in kind) from Medtronic. KN is a shareholder of Novo Nordisk, has received research support from Novo Nordisk, Roche Diagnostics and Zealand Pharma, has received lecture fees from Medtronic, Roche Diagnostics, Rubin Medical, Sanofi, Zealand Pharma, Novo Nordisk and Bayer, and has served on advisory panels for Medtronic, Abbott and Novo Nordisk. NSO has received honoraria for speaking and advisory board participation from Abbott Diabetes, Dexcom, Medtronic Diabetes and Roche Diabetes. DPZ has received speaker\u2019s honoraria from Medtronic Diabetes, Ascensia Diabetes and Insulet Corporation. TB has received honoraria for participation on advisory boards for Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic and Bayer HealthCare, and as a speaker for AstraZeneca, Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche, and owns stocks of DreaMed Diabetes. CDB has received speaker honoraria from MiniMed Medtronic and is a member of its European Psychology Advisory Board. RMBe has received research support from, consulted for or has been on a scientific advisory board for Abbott Diabetes Care, Dexcom, Eli Lilly, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi and United HealthCare. BB received grant support and advisory board fees from Medtronic Diabetes and ConvaTec, grant support and presentation fees from Insulet, advisory board fees from Novo Nordisk and Profusa, grant support from Eli Lilly, grant support and equipment from Dexcom, and is holding patent 61197230 on a hypoglycaemia prediction algorithm. EC is a scientific advisory board member/consultant for Novo Nordisk, Adocia, MannKind, Lexicon and Arecor, and a speaker for Novo Nordisk. TH is a shareholder of Profil, which has received research funds from Adocia, Boehringer Ingelheim, Dance Pharmaceuticals, Eli Lilly, Johnson & Johnson, MedImmune, Merck Sharp and Dohme, Mylan, Nordic Bioscience, Novo Nordisk, Poxel, Roche Diagnostics, Saniona, Sanofi, Senseonics and Zealand Pharma. SH has served as a consultant or speaker for Lilly, Novo Nordisk, Takeda, Boehringer Ingelheim, Mannkind, Sanofi-Aventis, Zealand Pharma and UN-EEG. LL reports having received speaker honoraria from Animas, Abbott, Insulet, Medtronic, Novo Nordisk, Roche and Sanofi, serving on advisory panels for Animas, Abbott, Novo Nordisk, Dexcom, Medtronic, Sanofi, and Roche, and research support from Novo Nordisk and Dexcom. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Hanmi Pharmaceuticals, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Dianax and UCB. CS reports having received speaker honoraria from Medtronic and Ypsomed, and serving on advisory panels for Novo Nordisk, Medtronic, Roche and Sanofi. MT has received speaker honoraria from MiniMed Medtronic and Novo Nordisk. EGW has received personal fees from Abbott Diabetes Care, Dexcom, Eli Lilly, Medtronic, Novo Nordisk and Sanofi-Aventis. HS has received honoraria, travel support or unrestricted research grants by Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi-Aventis. PGJ has a financial interest in Pacific Diabetes Technologies Inc., a company that may have a commercial interest in the results of this research and technology. RMBr has received honoraria as well as travel and educational grant support from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk and Sanofi-Aventis. JKM is a member of the advisory board of Boehringer Ingelheim, Eli Lilly, Medtronic, Prediktor A/S, Roche Diabetes Care and Sanofi, and received speaker honoraria from Abbott Diabetes Care, AstraZeneca, Dexcom, Eli Lilly, Medtronic, Merk Sharp & Dohme, Novo Nordisk A/S, Roche Diabetes Care, Sanofi, Servier and Takeda. The remaining authors have no relevant conflicts of interest to disclose.

PY - 2021/4

Y1 - 2021/4

KW - Blood Glucose

KW - Blood Glucose Self-Monitoring

KW - Diabetes Mellitus, Type 1

KW - Glucose

KW - Humans

KW - Hypoglycemia

UR - http://www.scopus.com/inward/record.url?scp=85100472600&partnerID=8YFLogxK

U2 - 10.1007/s00125-020-05374-3

DO - 10.1007/s00125-020-05374-3

M3 - Article

C2 - 33538843

SN - 0012-186X

VL - 64

SP - 935

EP - 938

JO - Diabetologia

JF - Diabetologia

IS - 4

ER -